1 |
Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL (2005). The 2005 International Society of Urological Pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma. Am J Surg Pathol, 29, 1228-42.
DOI
ScienceOn
|
2 |
Akaza H, Carroll P, Cooperberg MR, Hinotsu S (2012). Fifth joint meeting of J-CAP and capsure: advancing the global understanding of prostate cancer and its management. Jpn J Clin Oncol, 42, 226-36.
DOI
ScienceOn
|
3 |
Ataus S, Citci A, Alici B, et al (1999). The value of serum prostate specific antigen and other parameters in detecting bone metastases in prostate cancer. Int Urol Nephrol, 31, 481-9.
DOI
ScienceOn
|
4 |
Briganti A, Passoni N, Ferrari M, et al (2010). When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool. Eur Urol, 57, 551-8.
DOI
ScienceOn
|
5 |
Bubendorf L, Schopfer A, Wagner U, et al (2000). Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum pathol, 31, 578-83.
DOI
ScienceOn
|
6 |
Center MM, Jemal A, Lortet-Tieulent J, et al (2012). International variation in prostate cancer incidence and mortality rates. Eur Urol, 61, 1079-92.
DOI
ScienceOn
|
7 |
Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917.
DOI
ScienceOn
|
8 |
Haukaas S, Roervik J, Halvorsen OJ, Foelling M (1997). When is bone scintigraphy necessary in the assessment of newly diagnosed, untreated prostate cancer? Br J Urol, 79, 770-6.
DOI
|
9 |
Heidenreich A, Aus G, Bolla M, et al (2007). EAU Guidelines on Prostate Cancer. Eur Urol, 53, 68-80.
|
10 |
Ito K, Kubota Y, Suzuki K, et al (2000). Correlation of prostatespecific antigen before prostate cancer detection and clinicopathologic features: evaluation of mass screening populations. Urol, 55, 705-9.
DOI
ScienceOn
|
11 |
Jemal A, Center MM, DeSantis C, Ward EM (2010). Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev, 19, 1893-907.
DOI
ScienceOn
|
12 |
Mateen FJ, Shinohara RT, Carone M, et al (2012). Neurologic disorders incidence in HIV+ vs HIV- men: Multicenter AIDS Cohort Study, 1996-2011. Neurology, 79, 1873-80.
DOI
|
13 |
Kosuda S, Yoshimura I, Aizawa T, et al (2002). Can initial prostate specific antigen determinations eliminate the need for bone scans in patients with newly diagnosed prostate carcinoma? A multicenter retrospective study in Japan. Cancer, 94, 964-72.
DOI
ScienceOn
|
14 |
Lai MH, Luk WH, Chan JC (2011). Predicting bone scan findings using sPSA in patients newly diagnosed of prostate cancer: Feasibility in Asian population. Urol Oncol, 29, 275-9.
DOI
ScienceOn
|
15 |
Lin K, Szabo Z, Chin BB, Civelek AC (1999). The value of a baseline bone scan in patients with newly diagnosed prostate cancer. Clin Nucl Med, 24, 579-82.
DOI
|
16 |
Matsuda T, Saika K (2009). Comparison of time trends in prostate cancer incidence (1973-2002) in Asia, from cancer incidence in five continents, Vols IV-IX. Jpn J Clin Oncol 39, 468-9.
DOI
ScienceOn
|
17 |
Namiki M, Akaza H, Lee SE, et al (2010). Prostate cancer working group report. Jpn J Clin Oncol, 40, 70-5.
DOI
ScienceOn
|
18 |
Nguyen DX, Bos PD, Massague J (2009). Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer, 9, 274-84.
DOI
ScienceOn
|
19 |
Oesterling JE, Martin SK, Bergstralh EJ, Lowe FC (1993). The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA, 269, 57-60.
DOI
ScienceOn
|
20 |
Pal RP, Thiruudaian T, Khan MA (2008). When is a bone scan study appropriate in asymptomatic men diagnosed with prostate cancer? Asian J Androl, 10, 890-5.
DOI
ScienceOn
|
21 |
Wolff JM, Zimny M, Borchers H, et al (1998). Is prostatespecific antigen a reliable marker of bone metastasis in patients with newly diagnosed cancer of the prostate? Eur Urol, 33, 376-81.
DOI
ScienceOn
|
22 |
Quinn M, Babb P (2002). Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. BJU Int, 90, 162-73.
DOI
ScienceOn
|
23 |
Rudoni M, Antonini G, Favro M, et al (1995). The clinical value of prostate-specific antigen and bone scintigraphy in the staging of patients with newly diagnosed, pathologically proven prostate cancer. Eur J Nucl Med, 22, 207-11.
DOI
|
24 |
Sadik M, Suurkula M, Hoglund P, Jarund A, Edenbrandt L (2008). Quality of planar whole-body bone scan interpretations-a nationwide survey. Eur J Nucl Med Mol Imaging, 35, 1464-72.
DOI
|
25 |
Yang G, Zuo S, Ma C, et al (2009). The diagnostic correlations of bone scintigraphy, pathological grade and PSA for metastatic prostate cancers. The Chinese-German J Clinical Oncol, 8, 702-4.
DOI
|
26 |
Zaman MU, Fatima N, Sajjad Z (2011). Metastasis on bone scan with low prostate specific antigen (20 ng/ml) and Gleason's score (<8) in newly diagnosed Pakistani males with prostate cancer: should we follow Western guidelines? Asian Pac J Cancer Prev, 12, 1529-32.
|
27 |
McArthur C, McLaughlin G, Meddings RN (2012). Changing the referral criteria for bone scan in newly diagnosed prostate cancer patients. Br J Radiol, 85, 390-4.
DOI
ScienceOn
|